Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Financial Statements & Historical Data
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) — Price $43.10 (closing price, November 3, 2026) — Healthcare — Biotechnology — NASDAQ
Latest reported results:
Detailed financial statements for Hemab Therapeutics Holdings, Inc. Common Stock (COAG): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year: ten fiscal years free and up to 20 with Premium.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody.
At $43.10 (closing price, November 3, 2026), COAG has negative trailing earnings (P/E not meaningful) and an ROE of -36.64%. Market capitalisation stands at $2.0B.
Balance sheet quality for COAG: debt-to-equity ratio of 0.00, current ratio of 35.85 over the last 12 months, net cash position of $184.3M at the end of the last fiscal year. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Income Statement (10y)
Year
2025
Revenue
0
Cost of Revenue
0
Gross Profit
0
Research & Development
$59.6M
Selling, General & Admin
$10.5M
Operating Expenses
$70.1M
Operating Income
-$70.1M
EBITDA
-$69.8M
Interest Expense
0
Pre-tax Income
-$64.1M
Income Tax
-$227,000
Net Income
-$63.9M
EPS
-$2.33
EPS (Diluted)
-$2.33
Shares Outstanding (Diluted)
27.4 M
Income Statement (Quarterly)
Year
2026-Q1
2026-Q2
Revenue
0
0
Gross Profit
0
-$75,000
Operating Income
-$23.6M
-$26.1M
EBITDA
-$23.5M
-$26.0M
Net Income
-$22.7M
-$24.1M
EPS
-$0.51
-$0.80
EPS (Diluted)
-$0.51
-$0.80
Balance Sheet (10y)
Year
2025
Cash & Equivalents
$88.0M
Short-term Investments
$97.5M
Receivables
$2.6M
Inventory
0
Total Current Assets
$192.6M
Property, Plant & Equipment
$1.7M
Goodwill
0
Intangible Assets
0
Total Assets
$194.8M
Accounts Payable
$5.7M
Short-term Debt
0
Total Current Liabilities
$10.7M
Long-term Debt
0
Total Liabilities
$371.4M
Retained Earnings
-$181.9M
Total Equity
-$176.6M
Total Debt
$1.2M
Net Debt
-$184.3M
Working Capital
$181.9M
Balance Sheet (Quarterly)
Year
2026-Q1
2026-Q2
Cash & Equivalents
$49.9M
$237.4M
Total Assets
$175.3M
$467.8M
Total Liabilities
$373.9M
$13.5M
Total Equity
-$198.6M
$454.3M
Total Debt
$1.1M
$1.0M
Cash Flow (10y)
Year
2025
Net Income
-$63.9M
Depreciation & Amortization
$304,000
Stock-based Compensation
$2.0M
Change in Working Capital
$1.4M
Operating Cash Flow
-$61.5M
Capital Expenditure
-$16,000
Acquisitions
0
Stock Repurchased
0
Dividends Paid
0
Free Cash Flow
-$61.5M
Cash Flow (Quarterly)
Year
2026-Q1
2026-Q2
Operating Cash Flow
-$21.6M
-$22.6M
Capital Expenditure
-$112,000
$112,000
Free Cash Flow
-$21.7M
-$22.5M
Dividends Paid
0
0
Stock-based Compensation
$1.3M
0
Growth & Margins (10y)
Year
2025
Effective Tax Rate
0.4%
Per-Share Data (10y)
Year
2025
FCF Per Share
-$2.24
Dividends Per Share
$0.00
Shares Outstanding (Basic)
27.4 M
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap